Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has provided an update.
Lepu Biopharma Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for June 27, 2025, in Hong Kong. The meeting will address several key resolutions, including the approval of the 2024 annual report, financial accounts, and profit distribution plan, as well as the re-appointment of Ernst & Young as auditors. The AGM will also consider granting the Board a mandate to issue additional shares, which could impact the company’s strategic initiatives and shareholder value.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on the development and commercialization of innovative drugs and therapies, primarily targeting cancer treatment and other serious health conditions.
Average Trading Volume: 18,899,809
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.07B
See more data about 2157 stock on TipRanks’ Stock Analysis page.